Bevacizumab accelerates corneal wound healing by inhibiting TGF-β2 expression in alkali-burned mouse cornea

被引：26
作者：
Lee, Sung Ho [2 ]
Leem, Hyun-Sung [1 ]
Jeong, Seon Mi [2 ]
Lee, Koonja [1 ]
机构：
[1] Eulji Univ, Dept Optometry, Songnam 461713, South Korea
[2] Lumieye Genet Co Ltd, R&D Ctr, Seoul 135280, South Korea
来源：
BMB REPORTS | 2009年 / 42卷 / 12期
关键词：
Alkali burn; Bevacizumab; Cornea; TGF-beta; 2; Wound healing; NEOVASCULARIZATION; MYOFIBROBLAST; DIFFERENTIATION; ANGIOGENESIS; FIBROBLASTS; EPITHELIUM; AVASTIN; INJURY; STROMA; BETA;
D O I：
10.5483/BMBRep.2009.42.12.800
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
This study investigated the effect of subconjunctival injections of bevacizumab, an anti-VEGF antibody, on processes involved in corneal wound healing after alkali burn injury. Mice were divided into three groups: Group 1 was the saline-treated control, group 2 received subconjunctival injection of bevacizumab 1 hr after injury and group 3 received bevacizumab 1 hr and 4 days after injury. Cornea neovascularization and opacity were observed using a slit lamp microscope. Corneal repair was assessed through histological analysis and immunostaining for CD31, alpha-SMA, collagen 1, and TGF-beta 2 7 days post-injury. In group 3, injection of bevacizumab significantly lowered neovascularization and improved corneal transparency. Immuno-staining analysis demonstrated a reduction in CD31, alpha-SMA and TGF-beta 2 levels in stroma compared to group 1. These results indicate that bevacizumab may be useful in reducing neovascularization and improving corneal transparency following corneal alkali bum injury by accelerating regeneration of the basement membrane. [BMB reports 2009; 42(12): 800-805]
引用
收藏
页码：800 / 805
页数：6
相关论文
共 27 条
[1]   COMPLEX REGULATION OF TRANSFORMING GROWTH FACTOR-BETA-1, FACTOR-BETA-2, AND FACTOR-BETA-3 MESSENGER-RNA EXPRESSION IN MOUSE FIBROBLASTS AND KERATINOCYTES BY TRANSFORMING GROWTH FACTOR-BETA-1 AND FACTOR-BETA-2 [J].
BASCOM, CC ;
WOLFSHOHL, JR ;
COFFEY, RJ ;
MADISEN, L ;
WEBB, NR ;
PURCHIO, AR ;
DERYNCK, R ;
MOSES, HL .
MOLECULAR AND CELLULAR BIOLOGY, 1989, 9 (12) :5508-5515
[2]  
BURNS FR, 1990, INVEST OPHTH VIS SCI, V31, P107
[3]   Factors controlling ocular angiogenesis [J].
Casey, R ;
Li, WW .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1997, 124 (04) :521-529
[4]   Corneal neovascularization [J].
Chang, Jin-Hong ;
Gabison, Eric E. ;
Kato, Takuji ;
Azar, Dimitri T. .
CURRENT OPINION IN OPHTHALMOLOGY, 2001, 12 (04) :242-249
[5]  
CHUNG JH, 1989, ACTA OPHTHALMOL, V67, P685
[6]   Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival [J].
Cursiefen, C ;
Cao, JT ;
Chen, L ;
Liu, Y ;
Maruyama, K ;
Jackson, D ;
Kruse, FE ;
Wiegand, SJ ;
Dana, MR ;
Streilein, JW .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2004, 45 (08) :2666-2673
[7]   Pigment epithelium-derived factor: A potent inhibitor of angiogenesis [J].
Dawson, DW ;
Volpert, OV ;
Gillis, P ;
Crawford, SE ;
Xu, HJ ;
Benedict, W ;
Bouck, NP .
SCIENCE, 1999, 285 (5425) :245-248
[8]   Normal and pathologic soft tissue remodeling:: Role of the myofibroblast, with special emphasis on liver and kidney fibrosis [J].
Desmoulière, A ;
Darby, IA ;
Gabbiani, G .
LABORATORY INVESTIGATION, 2003, 83 (12) :1689-1707
[9]   Targeted deletion of AP-2α leads to disruption in corneal epithelial cell integrity and defects in the corneal stroma [J].
Dwivedi, DJ ;
Pontoriero, GF ;
Ashery-Padan, R ;
Sullivan, S ;
Williams, T ;
West-Mays, JA .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2005, 46 (10) :3623-3630
[10]   TGF-β1-mediated fibroblast-myofibroblast terminal differentiation -: the role of Smad proteins [J].
Evans, RA ;
Tian, YC ;
Steadman, R ;
Phillips, AO .
EXPERIMENTAL CELL RESEARCH, 2003, 282 (02) :90-100
123